(Sunday, 7/12/2020) [Eastern Time (GMT-4)]
Room: AAPM ePoster Library
Purpose:
Malignant melanoma is a highly aggressive skin cancer that tends to spread to other parts of the body.
[131I]ICF01012 is a new and patent radiopharmaceutic used in phase I clinical trial targeted radionuclide therapy (TRT) to treat melanoma. [131I]ICF01012 has been previously tested on mice bearing melanomas and on healthy rabbits.
This study intends to provide a personalized dosimetry in patients with pigmented metastatic melanoma included in a phase I clinical trial using the GATE platform. Dose to retina is particularly evaluated.
Methods:
Personalized dosimetry calculation is performed using the MIRD formalism. S values are calculated from patient CT scans using the GATE Monte Carlo platform. Time-integrated activities are obtained using SPECT-CT imaging (0.5, 1, 3, 24, 96, 168 hours post injection). Absorbed doses are provided to tumours and organs at risk: liver, kidneys, lungs, brain and retina.
Results:
The dosimetry study is performed on patients included on phase I clinical trial for injected activity from 800 MBq/m2 to 4000 MBq/m2 (36 patients). Doses to tumours and retina are the most significant compared to other organs. For 800 MBq/m2 injected activity, 6 Gy has been delivered to tumors and 1.4 Gy to retina.
Conclusion:
In this study, we demonstrate that personalized dosimetry calculation during phase I clinical transfer is totally feasible through the GATE platform in acceptable time. S-values can be calculated, with a 1% uncertainty, for each organ source within 4 hours using 10 CPUs.
Keywords
Not Applicable / None Entered.
Taxonomy
Not Applicable / None Entered.
Contact Email
